Biotech Is Back: Watch This $100 Billion Trend
After a rough bear market, it looks like biotech stocks are charging higher. Here's a trend that points to more ...
by Matthew Clark | Mar 18, 2024 | Money & Markets Daily
After a rough bear market, it looks like biotech stocks are charging higher. Here's a trend that points to more ...
by Michael Carr | Nov 29, 2023 | Money & Markets Daily
Trends in health care can become powerful tailwinds. Genomics is a good example of this. Here's how to find the ...
by Money and Markets Staff | Jan 18, 2023 | Investing
COVID-19 introduced a race for a vaccine, but how does Moderna stock (Nasdaq: MRNA) rate now that the pandemic is ...
by Adam O'Dell | Nov 7, 2022 | Investing
Midterm elections will change the political landscape in the U.S. But what about investment portfolios? Here's our top post-election tips.
by Adam O'Dell | Oct 17, 2022 | Investing
It's prudent to prepare for a recession now. When investing, that means targeting opportunities such as this health care mega ...
by Matthew Clark | Aug 16, 2022 | Investing
DVAX is a biopharma stock with promise as the company develops its signature hepatitis B vaccine. Here's why it's a ...
by Adam O'Dell | Feb 21, 2022 | Investing
Do you want to be a biotech value investor? It's possible to target solid companies trading at cheaper valuations in ...
by Adam O'Dell | Dec 27, 2021 | Investing
The biotech sector struggled in 2021, but the future is bright. The genomics mega trend will create life-changing wealth in ...
by Adam O'Dell | Dec 23, 2021 | Investing
Stock market mega trends are everywhere, but some are better than others. Here are five that should provide years of ...
by Adam O'Dell | Dec 10, 2021 | Investing
There are plenty of market mega trends to track in 2022. Here are three that chief investment strategist Adam O'Dell ...
In his free newsletter, What My System Says Today, Adam O’Dell uses his Green Zone Power Rating system to keep you in the know and focused on the market’s best (and worst) opportunities. It’s a data-driven approach underpinned by Wall Street-caliber tools you can only get here at Money & Markets. Sign up for FREE access to our daily emails now!
Enter your username and password below